Active, Not Recruiting
Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHN
NCT03726775
- Conditions
- Carcinoma, Carcinoma, Squamous Cell, HNSCC, +6 more
- Locations
-
- Institut Sainte Catherine Avignon, France
- Centre Eugene Marquis Rennes, France